Organoids: The Core Weapon of Precision Medicine

Precision medicine centers on realizing individualized diagnosis and treatment with one person, one tailored strategy, and organoid technology serves as the key to achieving this goal, regarded as the core powerhouse of precision medicine. It adopts human stem cells or the patient’s autologous tissues to develop miniature organ models via 3D in vitro culture, which highly restore the structure, functions and pathological characteristics of in vivo organs, act as an “in vitro substitute” for patients’ organs, perfectly replicate individual disease features, and thoroughly break through the precision bottlenecks of traditional diagnosis and treatment. Traditional 2D cell lines lose tumor heterogeneity, while animal models are plagued by interspecies differences. Both exhibit large deviations in drug susceptibility test results from clinical outcomes, easily leading to ineffective drug trials and sudden drug resistance. In contrast, organoids can retain gene mutations of primary lesions and the tissue microenvironment. The accuracy of drug susceptibility prediction for common cancers exceeds 80%, with some reaching nearly 95%. Furthermore, this technology covers the entire diagnosis and treatment chain including personalized medication, new drug research and development, and analysis of drug resistance mechanisms. At present, organoid drug susceptibility testing for high-incidence cancers has been incorporated into multiple clinical diagnosis and treatment guidelines, marking the entry of the technology into a mature translational stage. As a pioneer in the field of organoid technology, Suzhou XianJue Biotechnology Co., Ltd. drives the clinical application of this cutting-edge tool with robust core technologies. As a national high-tech enterprise, it relies on three core technologies: tumor organoids, iPSCs induced differentiation, and exosome capture & diagnosis, building China’s exclusive three-in-one technological platform featuring vascularization + immune microenvironment + AI closed-loop, which overcomes the core bottlenecks of traditional organoid culture. XianJue Biotechnology has established a full-industry-chain product system. Independently developed biomaterials such as organoid culture media and extracellular matrix bionic gels can construct organoids for over 90% of high-incidence tumors, boasting high biomimicry and safety. Its intelligent working system for organoid microphysiological models realizes full-process automation of culture, imaging, analysis and regulation. Combined with vascularized microphysiological model chips, it can accurately recapitulate human pathological features and stably culture organoids for more than 21 days, with far higher consistency of clinical prediction than traditional models. Meanwhile, XianJue Biotechnology keeps pace with domestic and international policy orientations and aligns with the national strategic layout of the organoid technology sector. Its products are applicable to multiple scenarios, including hospital drug susceptibility testing, model research at scientific research institutes, and new drug screening for pharmaceutical enterprises. The company has integrated the entire pathway from technological R&D to clinical translation, providing reliable support for precision medicine. It enables organoid technology to move from the laboratory to clinical practice, promotes the shift of diagnosis and treatment from experience-based judgment to data-driven decision-making, and practices the precision medicine philosophy of derived from the human body, applied to the human body. Founded in 2020, Suzhou XianJue Biotechnology Co., Ltd. (Suzhou XianJueBio) is an innovative biotechnology enterprise focusing on the R&D, transformation and promotion of new technologies. It has obtained the certifications of “National High-tech Enterprise” and “National Science and Technology-based Small and Medium-sized Enterprise”. Its products cover diverse fields such as individualized precision medicine, new drug R&D, and regenerative medicine. Supported by three core technological systems (tumor organoids, iPSCs induced differentiation, and disease-related exosome capture & diagnosis), the company has incubated a series of medical diagnostic and scientific research products. It owns multiple technical service platforms, including organoid model development, tumor organoid drug susceptibility testing, and research translation/new drug R&D. It also boasts world-leading technologies and R&D teams for primary/iPSCs-derived organoid culture media, extracellular matrix bionic gels, cytokines, intelligent working systems for organoid microphysiological models, vascularized microphysiological model chips, and exosome diagnostic chips.